+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Recombinant Uricase Market - Global Forecast 2026-2032- Product Image
Recombinant Uricase Market - Global Forecast 2026-2032- Product Image
Sale

Recombinant Uricase Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6055656
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Recombinant Uricase Market is projected to reach USD 684.31 Million in 2026. It is expected to continue growing at a CAGR of 8.72%, reaching USD 1.12 Billion by 2032.

Recombinant Uricase: Executive Overview

Recombinant uricase is an enzyme-based therapeutic approach designed to convert uric acid into more soluble metabolites. Its clinical relevance is concentrated in severe hyperuricemia, particularly where rapid urate reduction is needed or conventional urate-lowering approaches are insufficient. Adoption is shaped by treatment setting, patient selection, immunogenicity management, administration requirements, regulatory evidence, and access to specialist care.

Clinical Practice Is Shifting Toward Targeted, Monitored Treatment

The landscape is evolving from broad urate-lowering strategies toward more targeted use in patients with substantial disease burden or limited response to standard therapies. This shift increases the importance of baseline assessment, urate monitoring, infusion-related risk management, and protocols for identifying loss of response. Evidence generation is also moving beyond biochemical reduction to include durability, functional outcomes, treatment persistence, and patient quality of life.

Artificial Intelligence Strengthens Patient Selection and Safety Monitoring

Artificial intelligence can support recombinant uricase care by identifying patients at higher risk of severe hyperuricemia, integrating laboratory trends, and flagging potential treatment-response changes. Machine-learning tools may also assist with adverse-event surveillance, infusion monitoring, trial recruitment, and real-world evidence analysis. These applications remain dependent on validated datasets, transparent clinical governance, privacy controls, and prospective confirmation that algorithmic recommendations improve care rather than amplify selection bias.

Regional Insights: Access and Infrastructure Drive Adoption Differences

North America and Europe generally offer stronger specialist infrastructure, advanced laboratory monitoring, and established biologic-treatment pathways, while reimbursement rules and evidence requirements remain important constraints. Asia-Pacific combines substantial clinical need with wide variation in diagnostic capacity, regulatory processes, and access between urban and rural settings. Latin America is influenced by public procurement, specialist availability, and affordability considerations. The Middle East shows concentrated access through tertiary hospitals and well-funded health systems, whereas Africa faces greater variability in diagnostics, cold-chain capability, specialist coverage, and continuity of treatment. Across all regions, reliable urate testing and adverse-event management are foundational to responsible use.

Group Insights: Economic and Regulatory Blocs Shape Care Pathways

ASEAN markets are characterized by varied regulatory maturity, healthcare financing, and specialist access, making localized implementation important. BRICS countries combine large and diverse patient populations with differing domestic manufacturing capabilities, procurement systems, and clinical standards. The European Union emphasizes evidence, pharmacovigilance, and coordinated regulatory expectations alongside national reimbursement decisions. G7 systems typically have sophisticated specialty care and data infrastructure but apply rigorous cost-effectiveness and safety scrutiny. GCC countries benefit from concentrated tertiary-care networks and investment capacity, while NATO members span diverse health systems but often share strong emergency preparedness, clinical research, and biologic supply-chain capabilities.

Country Insights: National Systems Determine Clinical Integration

Australia and Canada rely on specialist-led care within publicly influenced reimbursement environments. Brazil and Mexico must balance tertiary-care capacity with unequal access across regions. China and India combine expanding clinical capabilities with major differences among provinces, cities, and facilities. France, Germany, Italy, Spain, and the United Kingdom operate within mature European evidence and safety frameworks, while reimbursement, referral pathways, and hospital protocols differ nationally. Japan and South Korea have advanced monitoring and specialist infrastructure with distinct regulatory and reimbursement requirements. Russia’s implementation is influenced by domestic supply, procurement, and specialist access. The United States has extensive specialty-care capacity, but coverage decisions, prior authorization, infusion infrastructure, and monitoring requirements can affect patient access.

Action Priorities for Leaders: Build Safe, Evidence-Based Treatment Pathways

Industry leaders should prioritize clearly defined patient-selection criteria, standardized pre-treatment assessment, and protocols for rapid identification of treatment failure or hypersensitivity. Investments in laboratory connectivity, cold-chain reliability, infusion capacity, and clinician education can improve continuity of care. Evidence programs should measure clinically meaningful outcomes, persistence, safety, and resource use across diverse populations. Responsible data and AI strategies should use validated models, human oversight, explainable outputs, and post-deployment monitoring. Regional partnerships with hospitals, payers, regulators, and patient organizations can help align access programs with local needs without weakening safety standards.

Research Methodology: Evidence-Led Assessment of the Recombinant Uricase Landscape

This executive summary uses the supplied market scope, recombinant uricase, as the analytical subject and organizes findings around clinical practice, technology, geography, economic groupings, and national health-system conditions. Insights are framed from established considerations in biologic therapy delivery, hyperuricemia management, regulatory oversight, reimbursement, pharmacovigilance, and healthcare infrastructure. No market estimates, market shares, forecasts, or company-specific claims are included. Interpretation should be validated against current clinical guidelines, regulatory documents, reimbursement policies, peer-reviewed evidence, and local treatment protocols before operational decisions are made.

Conclusion: Responsible Integration Depends on Evidence, Monitoring, and Access

Recombinant uricase occupies a specialized role where rapid or substantial urate reduction is clinically important. Its future integration will depend less on biochemical capability alone than on appropriate patient selection, immunogenicity and safety management, durable response assessment, and equitable access to specialist services. Health systems and industry leaders that combine rigorous evidence with dependable diagnostics, monitored administration, and accountable data use will be better positioned to translate the therapy’s potential into consistent patient benefit.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Recombinant Uricase Market, by Product Type
7.1. Introduction
7.2. Biosimilars of Recombinant Uricase
7.3. Non-Pegylated Uricase
7.4. Pegylated Uricase
8. Recombinant Uricase Market, by Route Of Administration
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous
8.4. Subcutaneous
9. Recombinant Uricase Market, by Application
9.1. Introduction
9.2. Cancer Treatment
9.3. Gout Treatment
9.3.1. Chronic Gout
9.3.2. Hyperuricemia
9.3.3. Refractory Gout
9.3.4. Tumor Lysis Syndrome
9.4. Kidney Diseases
9.5. Neurological Disorders
9.6. Rare Genetic Disorders
10. Recombinant Uricase Market, by End-User
10.1. Introduction
10.2. Healthcare Providers
10.2.1. Clinics
10.2.2. Dialysis Centers
10.2.3. Hospitals
10.3. Pharmaceutical Manufacturers
10.4. Research & Development Institutes
11. Recombinant Uricase Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Recombinant Uricase Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Recombinant Uricase Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. 3SBio Inc.
15.2. BioCryst Pharmaceuticals, Inc.
15.3. Biosynth Ltd
15.4. Creative Enzymes
15.5. CUSABIO TECHNOLOGY LLC
15.6. GenScript Biotech Corporation
15.7. Hzymes Biotech
15.8. Innovent Biologics, Inc.
15.9. Kikkoman Corporation
15.10. Merck KGaA
15.11. OYC Americas, Inc.
15.12. Protalix BioTherapeutics
15.13. Sisco Research Laboratories Pvt. Ltd.
15.14. Swedish Orphan Biovitrum AB
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Recombinant Uricase Market, Years Considered for the Study
FIGURE 2. Global Recombinant Uricase Market, Research Design
FIGURE 3. Global Recombinant Uricase Market, Research Framework
FIGURE 4. Global Recombinant Uricase Market, Data Triangulation
FIGURE 5. Global Recombinant Uricase Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Recombinant Uricase Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Recombinant Uricase Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Recombinant Uricase Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Recombinant Uricase Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Recombinant Uricase Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Recombinant Uricase Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Recombinant Uricase Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 13. Global Recombinant Uricase Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Recombinant Uricase Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Recombinant Uricase Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Recombinant Uricase Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Recombinant Uricase Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Recombinant Uricase Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Recombinant Uricase Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Recombinant Uricase Market Segmentation & Coverage
TABLE 2. Global Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 3. Global Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Biosimilars of Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biosimilars of Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biosimilars of Recombinant Uricase Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Non-Pegylated Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Non-Pegylated Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Non-Pegylated Uricase Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pegylated Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pegylated Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pegylated Uricase Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 14. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 24. Global Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Cancer Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Gout Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Gout Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Gout Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Chronic Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Chronic Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Chronic Gout Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Hyperuricemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Refractory Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Refractory Gout Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Tumor Lysis Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Tumor Lysis Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Tumor Lysis Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Kidney Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Kidney Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Kidney Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Rare Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Rare Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Rare Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 52. Global Healthcare Providers Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Healthcare Providers Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Healthcare Providers Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Dialysis Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Dialysis Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Dialysis Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Pharmaceutical Manufacturers Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Pharmaceutical Manufacturers Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Pharmaceutical Manufacturers Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Research & Development Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Research & Development Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Research & Development Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 78. North America Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. North America Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. North America Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 81. North America Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 82. North America Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 83. North America Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 84. North America Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 85. Latin America Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Latin America Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Latin America Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 88. Latin America Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. Latin America Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 90. Latin America Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 91. Latin America Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 92. Europe Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Europe Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 94. Europe Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 95. Europe Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 96. Europe Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 97. Europe Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 98. Europe Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 99. Middle East Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Middle East Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. Middle East Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 102. Middle East Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 103. Middle East Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 104. Middle East Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 105. Middle East Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 106. Africa Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Africa Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 108. Africa Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. Africa Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 110. Africa Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 111. Africa Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 112. Africa Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 113. Global Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. ASEAN Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 116. ASEAN Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 117. ASEAN Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 118. ASEAN Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 119. ASEAN Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 120. ASEAN Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 121. GCC Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. GCC Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. GCC Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 124. GCC Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 125. GCC Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 126. GCC Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 127. GCC Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 128. European Union Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. European Union Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 130. European Union Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. European Union Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 132. European Union Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 133. European Union Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 134. European Union Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 135. BRICS Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. BRICS Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. BRICS Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 138. BRICS Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 139. BRICS Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 140. BRICS Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 141. BRICS Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 142. G7 Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. G7 Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 144. G7 Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 145. G7 Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. G7 Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 147. G7 Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 148. G7 Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 149. NATO Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. NATO Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 151. NATO Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 152. NATO Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 153. NATO Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 154. NATO Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 155. NATO Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 156. Global Recombinant Uricase Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. United States Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 158. United States Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. United States Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 160. United States Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. United States Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 162. United States Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 163. United States Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 164. Canada Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 165. Canada Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 166. Canada Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. Canada Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 168. Canada Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 169. Canada Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 170. Canada Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 171. Mexico Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 172. Mexico Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Mexico Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 174. Mexico Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 175. Mexico Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 176. Mexico Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 177. Mexico Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 178. Brazil Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 179. Brazil Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. Brazil Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 181. Brazil Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 182. Brazil Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 183. Brazil Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 184. Brazil Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 185. United Kingdom Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 186. United Kingdom Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 187. United Kingdom Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. United Kingdom Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 189. United Kingdom Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 190. United Kingdom Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 191. United Kingdom Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 192. Germany Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 193. Germany Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 194. Germany Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 195. Germany Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 196. Germany Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 197. Germany Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 198. Germany Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 199. France Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 200. France Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. France Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 202. France Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 203. France Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 204. France Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 205. France Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 206. Russia Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 207. Russia Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. Russia Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. Russia Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. Russia Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 211. Russia Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 212. Russia Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 213. Italy Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 214. Italy Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 215. Italy Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 216. Italy Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 217. Italy Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 218. Italy Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 219. Italy Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 220. Spain Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 221. Spain Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 222. Spain Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 223. Spain Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 224. Spain Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 225. Spain Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 226. Spain Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 227. China Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 228. China Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. China Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 230. China Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 231. China Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 232. China Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 233. China Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 234. India Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 235. India Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. India Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 237. India Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 238. India Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 239. India Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 240. India Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 241. Japan Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 242. Japan Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 243. Japan Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 244. Japan Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 245. Japan Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 246. Japan Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 247. Japan Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 248. Australia Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 249. Australia Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 250. Australia Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 251. Australia Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 252. Australia Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 253. Australia Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 254. Australia Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 255. South Korea Recombinant Uricase Market Size, 2017-2032 (USD Million)
TABLE 256. South Korea Recombinant Uricase Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 257. South Korea Recombinant Uricase Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 258. South Korea Recombinant Uricase Market Size, by Application, 2017-2032 (USD Million)
TABLE 259. South Korea Recombinant Uricase Market Size, by Gout Treatment, 2017-2032 (USD Million)
TABLE 260. South Korea Recombinant Uricase Market Size, by End-User, 2017-2032 (USD Million)
TABLE 261. South Korea Recombinant Uricase Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 262. Global Recombinant Uricase Market Share, by Key Player, 2025
TABLE 263. Global Recombinant Uricase Market, Key Experts

Companies Mentioned

  • 3SBio Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Biosynth Ltd
  • Creative Enzymes
  • CUSABIO TECHNOLOGY LLC
  • GenScript Biotech Corporation
  • Hzymes Biotech
  • Innovent Biologics, Inc.
  • Kikkoman Corporation
  • Merck KGaA
  • OYC Americas, Inc.
  • Protalix BioTherapeutics
  • Sisco Research Laboratories Pvt. Ltd.
  • Swedish Orphan Biovitrum AB

Related Topics

Related Reports

Protein Therapeutics Market - Global Forecast 2026-2032 - Product Image

Protein Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Bioengineered Protein Drugs Market - Global Forecast 2026-2032 - Product Image

Bioengineered Protein Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Biopharmaceutical Market Size, Share, Trends and Forecast by Indication, Class, and Region, 2026-2034 - Product Image

Biopharmaceutical Market Size, Share, Trends and Forecast by Indication, Class, and Region, 2026-2034

  • Report
  • 142 Pages
  • Global
From
Biopharmaceutical Industry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Biopharmaceutical Industry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Recombinant Protein Therapeutics CDMO Market - Global Strategic Business Report - Product Image

Recombinant Protein Therapeutics CDMO Market - Global Strategic Business Report

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.